The Clinical Features of Metabolic Syndrome in Receptors of Hematopoietic Stem Cells.
10.19746/j.cnki.issn.1009-2137.2021.05.038
- Author:
Ye-Jun SI
1
;
Guo-Qiang LIN
2
;
Xing-Xia ZHANG
2
;
Mei-Ru BIAN
2
;
Li WANG
2
;
Miao WANG
2
;
Guang-Sheng ZHAO
2
;
Yan-Ming ZHANG
2
;
Qun SHEN
3
Author Information
1. Hematology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China,Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an Second People's Hospital, Huai'an 223002, Jiangsu Province, China.
2. Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an Second People's Hospital, Huai'an 223002, Jiangsu Province, China.
3. Hematology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China,E-mail: shenqun1016@163.com.
- Publication Type:Journal Article
- MeSH:
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells;
Humans;
Metabolic Syndrome;
Retrospective Studies;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2021;29(5):1610-1616
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the incidence and clinical characteristics of metabolic syndrome (MS) within one year after hematopoietic stem cell transplantation (HSCT) in order to screen the risk factors for HSCT-MS, provide early intervention and improve the long-term quality of survival of patients.
METHODS:The clinical follow-up data of 64 HSCT patients (survival time > 1 year) who received HSCT in our center from January 2007 to August 2018 were collected. Among them, 50 cases were allogeneic hematopoietic stem cell transplantation (allo-HSCT) and 14 cases were autologous hematopoietic stem cell transplantation (auto-HSCT). The changes of MS-related indexes and clinical characteristics before and 1, 3, 6 and 12 months after HSCT were analyzed retrospectively.
RESULTS:In allo-HSCT group, 14 cases were diagnosed as MS before operation, including high-density lipoprotein cholesterol (hypo-HDL-C)> hyper triglycerides（hyper-TG）> hyper fasting glucose（hyper-FBG）> abdominal obesity (AO) > hypertension. The preoperative diagnosis of MS in the auto-HSCT group was 5 cases, in the order of hyper-FBG> hyper-TG> AO> hypo-HDL-C> hypertension. Incidence of MS at 1, 3, 6 and 12 months after transplantation: 19, 26, 24 and 20 cases in the allo-HSCT group, respectively; auto-HSCT group were 7, 7, 6 and 6 cases, respectively. Hyper-TG and hypo-HDL-C were prominent in both groups.
CONCLUSION:The incidence of HSCT-MS is significantly higher within 1 year after HSCT. Regardless of allo-HSCT and auto-HSCT, the prevention and control of HSCT-MS is emphasized as an important guarantee to improve the long-term survival quality of HSCT patients.
